Last reviewed · How we verify
NCT05029349: VOC-BPCO
Exploration of the VOLATOLOM in the Stable Severe COPD (Chronic Obstructive Pulmonary Disease)
NA trial testing VOC analysis in Chronic Obstructive Pulmonary Disease Severe in 40 participants. Status unknown.
13 June 2023
Quick facts
| Lead sponsor | Hopital Foch |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 40 |
| Start date | 13 October 2021 |
| Primary completion | 13 June 2023 |
| Estimated completion | 13 June 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- VOC analysis
Conditions studied
- Chronic Obstructive Pulmonary Disease Severe — all drugs for Chronic Obstructive Pulmonary Disease Severe →
Sponsor
Hopital Foch — full company profile →
Who can join
Adults 40 to 85, any sex, with Chronic Obstructive Pulmonary Disease Severe. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective interventional study to determine whether the profile of volatile organic compounds (VOCs) present in exhaled air (VOLATOLOM) is reproducible in stable severe COPD (Chronic Obstructive Pulmonary Disease) patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05029349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of VOC analysis
Trials testing the same drug.
- NCT03988790 — Evaluation of the Response to Monoclonal Antibody Therapy in Severe Asthma: Research of Predictive Biomarkers in Exhaled · NA · unknown
- NCT03988192 — Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy for Lung Cancer: Research on Bi · NA · terminated
Other recruiting trials for Chronic Obstructive Pulmonary Disease Severe
Currently open trials in the same condition.
- NCT06198309 — Risk Prediction Model for Exacerbating Phenotype in Patients With Chronic Obstructive Pulmonary Disease · recruiting
- NCT06072690 — Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease · recruiting
- NCT04018729 — Cell Therapy Associated With Endobronchial Valve · Phase 2, PHASE3 · recruiting
Other Hopital Foch trials
Trials by the same sponsor.
- NCT06980844 — Interpretation of the Role of Eosinophils in Diffuse Interstitial Pneumopathies · NA · not yet recruiting
- NCT06757244 — DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer · Phase 2 · recruiting
- NCT06631794 — Evaluation of the Impact of a HPV Vaccination Talk with Third Grade Students · not yet recruiting
- NCT06533436 — Clinical and Economic Comparison of 2 Methods of Intubation Tube Fixation : AnchorFastTM Versus Current Cord Fixation · NA · recruiting
- NCT06476002 — Analysis of the Understanding of the French Version of the Vulvar Pain Assessment Questionnaire · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05029349 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hopital Foch
- Last refreshed: 28 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05029349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing